Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Pexidartinib in Moderate Hepatic Impairment
NCT04223635Phase 1Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jan 2020
- Primary completion
- Oct 2020
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of pexidartinib in tenosynovial giant cell tumor (TGCT), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Maximum Plasma Concentration of Pexidartinib at 168 hours, Time of Maximum Plasma Concentration of Pexidartinib and 6 more. Started Jan 2020; status: completed.
02
Drugs
pexidartinib
03
Conditions
tenosynovial giant cell tumor (TGCT)
Beyond the preview
Go deeper on NCT04223635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04223635.